Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Davy Crockett who wrote (3737)	5/10/2001 4:41:30 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

OT to svenlar; I don't know what the objective of your post to Peter was. A personal attack on this thread's originator and major contributor is unlikely to get you any sympathy, empathy or anything else. All that you've achieved, with me at least, is lowered credibility. Ian

To: Davy Crockett who wrote (3737)	5/10/2001 4:55:41 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

svenlar, I think you seriously misinterpreted my quickie post. Just to set matters straight: 1. I am delighted that the FDA emerged from its current torpor and approved the drug in record time. I certainly did not mean to imply in any way that the FDA should have been slower here. 2. The drug is a fantastic drug, and kudos to Novartis for bringing it to the market as quickly as they did. 3. A bunch more drugs like this and many fewer people will have to face losing loved ones to cancer or have to face the rigors of chemotherapy. Can't happen fast enough as far as I am concerned. I am sorry you had to face losing your brother - I think all of us have had loved ones lost to cancer and other bad diseases. 4. It's sometimes hard to balance the ethics of investment with the real-world impact of one's actions. Like it or not investors have an impact (albeit small) on the real world companies we invest in. That's why I have an abhorrence of shorts who publicly attack good companies just to try to make a buck or two. I am personally delighted whenever a good new drug emerges, even it it happens to have a negative effect on my personal portfolio (which Gleevec doesn't). 5. I kid around a lot, and certainly didn't mean to upset anyone with my rather glib post on a serious subject. Peter